233 related articles for article (PubMed ID: 24440307)
1. Promising roles of mammalian E2Fs in hepatocellular carcinoma.
Zhan L; Huang C; Meng XM; Song Y; Wu XQ; Miu CG; Zhan XS; Li J
Cell Signal; 2014 May; 26(5):1075-81. PubMed ID: 24440307
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.
Baiz D; Dapas B; Farra R; Scaggiante B; Pozzato G; Zanconati F; Fiotti N; Consoloni L; Chiaretti S; Grassi G
World J Gastroenterol; 2014 Jan; 20(3):795-803. PubMed ID: 24574752
[TBL] [Abstract][Full Text] [Related]
3. Cloning and characterization of mouse E2F8, a novel mammalian E2F family member capable of blocking cellular proliferation.
Maiti B; Li J; de Bruin A; Gordon F; Timmers C; Opavsky R; Patil K; Tuttle J; Cleghorn W; Leone G
J Biol Chem; 2005 May; 280(18):18211-20. PubMed ID: 15722552
[TBL] [Abstract][Full Text] [Related]
4. Expression and prognostic role of E2F transcription factors in high-grade glioma.
Yu H; Li Z; Wang M
CNS Neurosci Ther; 2020 Jul; 26(7):741-753. PubMed ID: 32064771
[TBL] [Abstract][Full Text] [Related]
5. E2F8 contributes to human hepatocellular carcinoma via regulating cell proliferation.
Deng Q; Wang Q; Zong WY; Zheng DL; Wen YX; Wang KS; Teng XM; Zhang X; Huang J; Han ZG
Cancer Res; 2010 Jan; 70(2):782-91. PubMed ID: 20068156
[TBL] [Abstract][Full Text] [Related]
6. Impairment of the Pin1/E2F1 axis in the anti-proliferative effect of bortezomib in hepatocellular carcinoma cells.
Farra R; Dapas B; Baiz D; Tonon F; Chiaretti S; Del Sal G; Rustighi A; Elvassore N; Pozzato G; Grassi M; Grassi G
Biochimie; 2015 May; 112():85-95. PubMed ID: 25742740
[TBL] [Abstract][Full Text] [Related]
7. Prognostic values of
Manicum T; Ni F; Ye Y; Fan X; Chen BC
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30487158
[TBL] [Abstract][Full Text] [Related]
8. PEG10 directly regulated by E2Fs might have a role in the development of hepatocellular carcinoma.
Wang C; Xiao Y; Hu Z; Chen Y; Liu N; Hu G
FEBS Lett; 2008 Aug; 582(18):2793-8. PubMed ID: 18625225
[TBL] [Abstract][Full Text] [Related]
9. E2F transcription factors and digestive system malignancies: how much do we know?
Xanthoulis A; Tiniakos DG
World J Gastroenterol; 2013 Jun; 19(21):3189-98. PubMed ID: 23745020
[TBL] [Abstract][Full Text] [Related]
10. E2f8 mediates tumor suppression in postnatal liver development.
Kent LN; Rakijas JB; Pandit SK; Westendorp B; Chen HZ; Huntington JT; Tang X; Bae S; Srivastava A; Senapati S; Koivisto C; Martin CK; Cuitino MC; Perez M; Clouse JM; Chokshi V; Shinde N; Kladney R; Sun D; Perez-Castro A; Matondo RB; Nantasanti S; Mokry M; Huang K; Machiraju R; Fernandez S; Rosol TJ; Coppola V; Pohar KS; Pipas JM; Schmidt CR; de Bruin A; Leone G
J Clin Invest; 2016 Aug; 126(8):2955-69. PubMed ID: 27454291
[TBL] [Abstract][Full Text] [Related]
11. Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription.
Christensen J; Cloos P; Toftegaard U; Klinkenberg D; Bracken AP; Trinh E; Heeran M; Di Stefano L; Helin K
Nucleic Acids Res; 2005; 33(17):5458-70. PubMed ID: 16179649
[TBL] [Abstract][Full Text] [Related]
12. The ancient function of RB-E2F pathway: insights from its evolutionary history.
Cao L; Peng B; Yao L; Zhang X; Sun K; Yang X; Yu L
Biol Direct; 2010 Sep; 5():55. PubMed ID: 20849664
[TBL] [Abstract][Full Text] [Related]
13. Promising diagnostic and prognostic value of E2Fs in human hepatocellular carcinoma.
Huang YL; Ning G; Chen LB; Lian YF; Gu YR; Wang JL; Chen DM; Wei H; Huang YH
Cancer Manag Res; 2019; 11():1725-1740. PubMed ID: 30863181
[TBL] [Abstract][Full Text] [Related]
14. E2F-6: a novel member of the E2F family is an inhibitor of E2F-dependent transcription.
Cartwright P; Müller H; Wagener C; Holm K; Helin K
Oncogene; 1998 Aug; 17(5):611-23. PubMed ID: 9704927
[TBL] [Abstract][Full Text] [Related]
15. Role of E2F transcription factor in oral cancer: Recent insight and advancements.
Kassab A; Gupta I; Moustafa AA
Semin Cancer Biol; 2023 Jul; 92():28-41. PubMed ID: 36924812
[TBL] [Abstract][Full Text] [Related]
16. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
[TBL] [Abstract][Full Text] [Related]
17. Structural insights into the DNA-binding specificity of E2F family transcription factors.
Morgunova E; Yin Y; Jolma A; Dave K; Schmierer B; Popov A; Eremina N; Nilsson L; Taipale J
Nat Commun; 2015 Dec; 6():10050. PubMed ID: 26632596
[TBL] [Abstract][Full Text] [Related]
18. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
Qi R; An H; Yu Y; Zhang M; Liu S; Xu H; Guo Z; Cheng T; Cao X
Cancer Res; 2003 Dec; 63(23):8323-9. PubMed ID: 14678992
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of E2F5/p130, but not E2F5 alone, can inhibit E2F-induced cell cycle entry in transgenic mice.
Chen Q; Liang D; Overbeek PA
Mol Vis; 2008 Mar; 14():602-14. PubMed ID: 18385796
[TBL] [Abstract][Full Text] [Related]
20. Cellular transformation of mouse embryo fibroblasts in the absence of activator E2Fs.
Gupta T; Sáenz Robles MT; Pipas JM
J Virol; 2015 May; 89(9):5124-33. PubMed ID: 25717106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
